10 August 2022

Unravelling genetic mechanism behind tumor formation can improve targeted treatment

Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical responses to available therapies remained variable and unpredictable, making it difficult to select patients who would benefit from these types of treatments. An international team of researchers led by Jos Jonkers, group leader at the Netherlands Cancer Institute and Oncode Investigator, has now elucidated the mechanism behind this variation in treatment response. Their research offers new opportunities to improve diagnostics and targeted therapy for many cancer patients. The results highlight the importance of studying the functional consequences of genetic changes in tumors.

Peter Thijssen Support Staff

In various types of cancers - including bile duct cancer, stomach cancer and breast cancer - copy number alterations and fusions in the Fibroblast Growth Factor Receptor 2 (FGFR2) gene are relatively common. But just how these genetic variations contribute to the formation of tumors was unclear. Besides this, targeting FGFR2 with therapies brought variable and unpredictable results. But now the team led by Oncode Investigator Jos Jonkers took a data driven approach to solve this puzzle presented by FGFR2.

“The story of our new findings began over a decade ago”, says Jonkers who is a group leader at the Netherlands Cancer Institute. “By using a mouse model in which we could induce genetic alterations in a controlled manner, we observed a specific variation in the last part of the FGFR2 gene leading to the presence of an incomplete FGFR2 protein. Follow up mouse experiments then showed that this truncated form of FGFR2 leads to the formation of tumors.”

Tumor formation is not caused by more of the normal protein, but by a little bit of the truncated protein

In parallel, the team started looking for evidence of the presence of this truncated form of FGFR2 in human cancer samples. With the datasets available at the Hartwig Medical Foundation and Foundation Medicine, they uncovered that many of the known alterations in the FGFR2 gene lead to the expression of the truncated protein. “We found data confirming our model at the genetic level, but also at the gene expression level”, postdoctoral fellow and first author Daniel Zingg explains. “Existing diagnostic approaches usually focus on the increased amounts of the protein in tumor samples. What we uncovered now is that it is not the amount of FGFR2 what is causing cells to become cancerous, but the expression of the truncated form. Tumor formation is not caused by more of the normal protein, but by a little bit of the truncated protein."

Clinical impact

To determine the clinical relevance of their findings, the team interrogated data from preclinical and clinical trials with FGFR inhibitors from biopharmaceutical companies Debiopharm and Incyte, respectively. “We knew that our preclinical findings had the potential to change clinical practice”, says Jonkers. “Looking into clinical trial data revealed that a good response to treatment correlates with the presence of the truncated form of FGFR2. This means that we now have a way to identify which patients can benefit from treatments targeting FGFR2.” The results should still be confirmed in a prospective clinical trial, but the team is very hopeful that their work can help to improve the clinical practice.

The results published in Nature showcase the importance of collaboration as well as a data driven approach. The team of Jos Jonkers collaborated with fellow Oncode Investigator and co-cooresponding author Lodewyk Wessels, other Oncode Investigators, colleagues at the NKI, Amsterdam UMC, Hartwig Medical Foundation, genomic profiling company Foundation Medicine, biopharmaceutical companies Incyte and Debiopharm and Rutgers Cancer Institute of New Jersey. “These findings, which go from mouse models into cancer genomics and human clinical trial data, will lay the groundwork for development of clinical trials aimed at rationally increasing the number of patients who will benefit from FGFR inhibitor therapy,” says Shridar Ganesan, MD, PhD, chief of molecular oncology and associate director for translational research at Rutgers Cancer Institute and co-senior author of the work. “This work also demonstrates the growing power of using clinical tumor sequencing data and sophisticated pre-clinical models to tackle basic questions in tumorigenesis and guide development of targeted therapeutics.”

“It’s great that through our Oncode base funding and a broad collaborative effort, we could bring this basic and data driven project towards the point where we can have a clinical impact. From a scientific perspective, our work highlights the importance of the functional analysis of mutations we find in cancer. This will allow us to better interpret the ever-growing set of genetic data from tumors, and advance our understanding of cancer biology”, Jonkers concludes.

Read the scientific article here.

Other News

Meeting researchers’ needs: Advanced workshop Preclinical tumor immune models for therapeutic discovery and validation
With more than a hundred participants covering a broad community interested in the OI field, this successful advanced workshop featured an exciting programme.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
2 2
Highlights of the European Society of Medical Oncology Congress 2022 in Paris
Are you curious about the highlights of the European Society of Medical Oncology Congress 2022 in Paris? Oncode's Yuva Oz was there to report about all of the interesting and relevant data presented.


Over 17 years of experience in Molecular Biology, Yuva completed her MSc. degree at EMBL Heidelberg and conducted her PhD research on the topic of Chromatin and Biomedical Genetics at Hubrecht Institute as a Marie-Curie fellow. Interested in clinical aspects of the research, she joined to oncology specialized clinical research organization SMS-oncology, gaining experience both in clinical trial management (early phase paediatric and adult trials) and Business Development aspects. At Oncode, she is driving the industry engagement programme to enable new alliances and collaborations between Oncode and biopharma to fast-forward research and innovation. Furthermore, working closely with Oncode Investigators, she supports technology, clinical and IP assessments for efficiently translating fundamental research into clinical benefit. She is the founder and designer at Art 4 Science, a scientific visualization – graphic design company.
4.UNCAN.eu is officially launching today!
Oncode is pleased to take part in the kick-off meeting of the CSA (Coordination and Support Action) for the 4.UNCAN.eu initiative, taking place today and tomorrow in Paris. Arising from the EU’s Mission on Cancer and Europe’s Beating Cancer plan, the initiative is focused on generating a research roadmap to better UNderstand poorly understood CANcers (UNCAN).